Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 720M 628M 593M 539M 1.01B 69.13B 1.01B 7.11B 2.74B 35.15B 2.71B 2.65B 113B P/E 2026 *
3.56x
P/E 2027 * 3.31x
Enterprise Value 720M 628M 593M 539M 1.01B 69.13B 1.01B 7.11B 2.74B 35.15B 2.71B 2.65B 113B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.46x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+3.07%
1 week+6.86%
Current month+2.59%
1 month+1.16%
3 months+23.16%
6 months+37.54%
Current year+29.38%
1 week 4.04
Extreme 4.045
4.48
1 month 3.94
Extreme 3.94
4.48
Current year 2.95
Extreme 2.95
5.78
1 year 1.26
Extreme 1.26
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/9/26 Free

Director

3,694 0.0022%
20/7/26 Free

Chief Technology Officer

137,036 0.0832%
7/7/26 Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
+3.07%+6.86%+198.63%-49.36% 720M
-0.19%+2.04%+80.14%+36.22% 362B
-1.22%-1.22%+20.85%-19.25% 64.74B
+2.53%+4.90%+46.65%+187.52% 12.76B
-0.29%+2.94%-6.00%-16.54% 7.53B
-1.89%-2.14%-27.99%-15.17% 4.38B
-2.06%-4.41%-35.13%+4.31% 4.08B
+1.48%+3.64%-31.47%-15.12% 2.96B
-2.14%+0.86%-8.95%+48.36% 2.44B
-0.41%+1.15%-26.86%-33.47% 1.93B
Average -0.11%+1.14%+20.99%+12.75% 46.39B
Weighted average by Cap. -0.29%+1.57%+66.07%+30.33%

Financials

2026 *2027 *
Net sales 471M 411M 388M 352M 660M 45.24B 663M 4.65B 1.79B 23B 1.77B 1.73B 74B 494M 431M 407M 369M 692M 47.41B 695M 4.87B 1.88B 24.1B 1.86B 1.81B 77.55B
Net income 203M 177M 167M 152M 285M 19.5B 286M 2B 774M 9.92B 764M 747M 31.91B 220M 192M 181M 164M 308M 21.1B 309M 2.17B 837M 10.73B 826M 808M 34.51B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
18/09/26 USD 4.360 +3.07% 7,691,287
17/09/26 USD 4.230 +1.44% 3,486,907
16/09/26 USD 4.170 +2.71% 1,312,800
15/09/26 USD 4.060 -2.64% 1,124,738
14/09/26 USD 4.170 +2.21% 1,252,649
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.360USD
Average target price
6.100USD
Spread / Average Target
+39.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!